ASM-024
Phase 2- Indications
- Asthma, COPD
Company intelligence / Profile preview
Asmacure Ltée
Quebec, Quebec, Canadadnb.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company has conducted clinical trials with ASM-024 dry powder for inhalation. In 2013, they dosed first subjects with this formulation[5]. They have presented clinical updates for ASM-024 DPI in multiple studies[7].
- Therapeutic areas
- Pulmonology
- Modalities
- Small molecules (nicotinic receptor agonists)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Asmacure Ltée.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asmacure Ltée.